Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.

DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.

NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down

by Zacks Equity Research

NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.

CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.

Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised

by Zacks Equity Research

Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.

Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.

Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.

Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View

by Zacks Equity Research

Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.

AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View

by Zacks Equity Research

Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.

Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised

by Zacks Equity Research

Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.

Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit

by Zacks Equity Research

Tenet Healthcare's (THC) Q2 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.18-$6.03 for this year.

Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across all segments drives its Q2 sales, despite business challenges.

Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

Strength in Breast Health and GYN Surgical drives Hologic's (HOLX) Q3 performance.

IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.

Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised

by Zacks Equity Research

Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.

Zacks Industry Outlook Highlights Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics

by Zacks Equity Research

Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics are part of the Zacks Industry Outlook article.

Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised

by Zacks Equity Research

Despite Avantor's (AVTR) strength in end markets, it reports an overall soft second-quarter performance.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy Amid Recovering Prospects

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.

Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up

by Zacks Equity Research

Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip

by Zacks Equity Research

Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.

Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut

by Zacks Equity Research

In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.

DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.

LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline

by Zacks Equity Research

A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.